Condition: Non-Muscle-Invasive Bladder Cancer (NMIBC) · Sponsor: Ractigen Therapeutics.
This is an open label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with NMIBC who have failed BCG therapy.
This description comes directly from the study's public registry record.
Long-Cheng Li · +86 18051622388 · lilc@ractigen.com
Always discuss trial participation with your own doctor first.
| GenesisCare North Shore | St Leonards, New South Wales, Australia | Recruiting |
| The Royal Melbourne Hospital | Melbourne, Victoria, Australia | Recruiting |
| Peninsula & South Eastern Haematology and Oncology Group | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06351904